US Dollar vs Yen

登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
OKYO Pharma Ltd (OKYO)
OKYO Pharma Ltd (OKYO) ニュース

OKYO

OKYO Pharma (OKYO)

OKYO Pharma Ltd

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:OKYO

1 2 3 4 5 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/08	20 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:OKYO	OKYO Pharma Ltd
2024/05/08	20 : 00	GlobeNewswire Inc.	OKYO Pharma Announces Participation in May 2024 Investor Conferences	NASDAQ:OKYO	OKYO Pharma Ltd
2024/04/30	20 : 00	GlobeNewswire Inc.	OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)	NASDAQ:OKYO	OKYO Pharma Ltd
2024/04/09	08 : 00	GlobeNewswire Inc.	OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024	NASDAQ:OKYO	OKYO Pharma Ltd
2024/04/02	20 : 00	GlobeNewswire Inc.	OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery	NASDAQ:OKYO	OKYO Pharma Ltd
2024/03/22	20 : 00	GlobeNewswire Inc.	OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101	NASDAQ:OKYO	OKYO Pharma Ltd
2024/03/21	20 : 00	GlobeNewswire Inc.	OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial	NASDAQ:OKYO	OKYO Pharma Ltd
2024/03/20	20 : 00	GlobeNewswire Inc.	OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event	NASDAQ:OKYO	OKYO Pharma Ltd
2024/02/09	21 : 36	InvestorsHub NewsWire	OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain	NASDAQ:OKYO	OKYO Pharma Ltd
2024/02/09	21 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:OKYO	OKYO Pharma Ltd
2024/02/09	21 : 00	GlobeNewswire Inc.	OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain	NASDAQ:OKYO	OKYO Pharma Ltd
2024/01/31	21 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:OKYO	OKYO Pharma Ltd
2024/01/31	21 : 00	GlobeNewswire Inc.	OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board	NASDAQ:OKYO	OKYO Pharma Ltd
2024/01/08	21 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:OKYO	OKYO Pharma Ltd
2024/01/08	21 : 00	GlobeNewswire Inc.	OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease	NASDAQ:OKYO	OKYO Pharma Ltd
2024/01/05	23 : 30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:OKYO	OKYO Pharma Ltd
2024/01/05	23 : 30	GlobeNewswire Inc.	OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024	NASDAQ:OKYO	OKYO Pharma Ltd
2023/12/21	21 : 35	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:OKYO	OKYO Pharma Ltd
2023/12/21	07 : 30	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:OKYO	OKYO Pharma Ltd
2023/12/19	06 : 56	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:OKYO	OKYO Pharma Ltd
2023/12/04	21 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:OKYO	OKYO Pharma Ltd
2023/12/04	21 : 00	GlobeNewswire Inc.	OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit	NASDAQ:OKYO	OKYO Pharma Ltd
2023/11/29	21 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:OKYO	OKYO Pharma Ltd
2023/11/02	05 : 55	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:OKYO	OKYO Pharma Ltd
2023/11/01	05 : 59	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:OKYO	OKYO Pharma Ltd
2023/10/31	20 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:OKYO	OKYO Pharma Ltd
2023/10/31	20 : 00	GlobeNewswire Inc.	OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction	NASDAQ:OKYO	OKYO Pharma Ltd
2023/10/10	20 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:OKYO	OKYO Pharma Ltd
2023/10/10	00 : 34	InvestorsHub NewsWire	OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain ("NCP")	NASDAQ:OKYO	OKYO Pharma Ltd
2023/10/09	20 : 00	GlobeNewswire Inc.	OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)	NASDAQ:OKYO	OKYO Pharma Ltd

Showing the most relevant articles for your search:NASDAQ:OKYO

1 2 3 4 5 次へ >>

BNP Paribas (QX)

US Dollar vs Euro

Energy Select Sector SPDR

US Dollar vs Yen

Invesco QQQ Trust Series 1

Health Care Select Sector

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約